Company Profile

Shengtai Pharmaceutical, Inc. (Shengtai), through its wholly owned subsidiary, Weifang Shengtai Pharmaceutical Inc., is a producer of pharmaceutical-grade glucose in China. The Company's products include pharmaceutical-grade glucose or dextrose, used for medical purposes, as well as other glucose and cornstarch products used for the food and beverage industry, and for industrial productions in China. The Company's glucose series include dextrose monohydrate (DMH), dextrose anhydrous, oral glucose dextrin and rough glucose for other processing purposes. Its starch series include pharmaceutical starch and edible corn starch. The Company's customers include healthcare institutions, food and beverage companies, pharmaceutical companies, medical supply exporters and medical supply. The Company also exports its products to approximately 70 different countries overseas, such as Japan, Singapore, Korea, Australia, Russia and India.

Employees

733

Sector

Pharmaceuticals

More about the company

24/07/13	Qingtai Liu, Chairman and Chief Executive Officer of Shengtai Pharmaceutical Inc. cancelled the acquisition of the remaining 59.5% stake in Shengtai Pharmaceutical Inc. from Pope Investments LLC, a fund of Pope Asset Management, LLC and other investors.	CI
16/05/13	Shengtai Pharmaceutical Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2013	CI
15/02/13	Shengtai Pharmaceutical Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2012	CI
15/11/12	Shengtai Pharmaceutical Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended September 30, 2012	CI
29/09/12	Shengtai Pharmaceutical Inc. Announces Consolidated Earnings Results for the Year Ended June 30, 2012	CI
16/05/12	Shengtai Pharmaceutical Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2012	CI
17/04/12	Qingtai Liu, Chairman and Chief Executive Officer of Shengtai Pharmaceutical Inc. made an offer to acquire remaining 59.5% stake in Shengtai Pharmaceutical Inc. from Pope Investments LLC, a fund of Pope Asset Management, LLC and other investors for $9.4 million.	CI
15/02/12	Shengtai Pharmaceutical Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2011	CI

Director	Title	Age	Since
Qing Tai Liu CHM	Chairman	67	-
Yong Qiang Wang BRD	Director/Board Member	56	14/04/2011
Ji Hui Hao BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SHENGTAI PHARMACEUTICAL, INC.	-.--%	-100.00%	-	-	9
ELI LILLY AND COMPANY	-0.61%	-3.43%	+36.07%	+115.04%	1,019B
JOHNSON & JOHNSON	-1.02%	-5.60%	+35.72%	+64.63%	617B
ABBVIE INC.	+1.11%	-0.58%	+12.36%	+77.95%	464B
MERCK & CO., INC.	+0.34%	-3.01%	+61.79%	+41.24%	356B
ROCHE HOLDING AG	+1.30%	-1.63%	+21.22%	+41.71%	333B
NOVARTIS AG	+1.19%	-3.15%	+11.13%	+34.79%	267B
ASTRAZENECA PLC	+0.45%	-4.82%	-6.57%	+9.06%	244B
AMGEN INC.	-1.04%	-2.79%	+35.30%	+51.84%	218B
GILEAD SCIENCES, INC.	-1.87%	-4.10%	+28.44%	+93.66%	179B
Average	-0.03%	-3.54%	+26.16%	+58.88%	410.8B
Weighted average by Cap.	+0.10%	-3.54%	+29.15%	+70.72%

Shengtai Pharmaceutical, Inc. Stock

Stocks

SGTI

US8232142005

Pharmaceuticals

Latest news: Shengtai Pharmaceutical, Inc.

Managers and Directors: Shengtai Pharmaceutical, Inc.

Generic Pharmaceuticals

Company Profile